AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06496919
Drug: Recombinant Mutant Human Tumor Necrosis Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
Trial: NCT05682495
Drug: ARM A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
Trial: NCT05682495
Drug: ARM B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Trial: NCT05682495
Drug: ARM C
RxNorm normalized name: Forearm Crutch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Trial: NCT05682495
Drug: ARM D
RxNorm normalized name: Clever Choice BP Monitor/Arm Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
Trial: NCT05682495
Drug: ARM E
RxNorm normalized name: Clever Choice Upper Arm Elite Blood Pressure Monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
Trial: NCT05682495
Drug: ARM F
RxNorm normalized name: Scheinpharm FLUoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
Trial: NCT05427253
Drug: C106 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
Trial: NCT05427253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for C106 solution
Trial: NCT05241821
Drug: Thrombolytic Agent
RxNorm normalized name: Thrombolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug aimed to dissolve thrombus affecting the cerebral circulation
Trial: NCT06412497
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines.
Trial: NCT05822544
Drug: TLC-6740 Oral Solution
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of TLC-6740
Trial: NCT05822544
Drug: TLC-6740 Tablet
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of TLC-6740
Trial: NCT05822544
Drug: Drug Metabolizing Enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of omeprazole, voriconazole, or itraconazole
Trial: NCT05838729
Drug: RiMO-301
RxNorm normalized name: Rimoxyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions.
Trial: NCT05437575
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl citrate 10mcg/ml packaged in pre-filled syringe
Trial: NCT05797610
Drug: sefaxersen (RO7434656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sefaxersen (RO7434656) will be administered subcutaneously per schedule as specified.
Trial: NCT05797610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously per schedule as specified.
Trial: NCT05071937
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
Trial: NCT04450953
Drug: Eplerenone 50mg/day (cross over design)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50mg/day for 6 months followed
Trial: NCT06798662
Drug: Drug (famciclovir and gabapentin)
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
Trial: NCT04948788
Drug: SHR1459 ；YY-20394
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR1459 plus YY-20394
Trial: NCT06426485
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day
Trial: NCT05297201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
Trial: NCT04628767
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given Iv
Trial: NCT04628767
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06028074
Drug: GIM122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIM-122 administered IV once every 3 weeks or every 2 weeks
Trial: NCT05189457
Drug: New Hormonal Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
Trial: NCT05351502
Drug: Nitric Oxide 25,000 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of 25,000 gNO
Trial: NCT05351502
Drug: Nitric Oxide 50,000 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of 50000 gNO
Trial: NCT05351502
Drug: Nitric Oxide 100,000 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of 100,000 gNO
Trial: NCT05351502
Drug: Nitric Oxide selected dose
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of selected does on gNO
Trial: NCT03617445
Drug: FMT oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules, single dose of 5 capsules
Trial: NCT06445881
Drug: Modified Si Jun Zi Tang
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
Trial: NCT06528665
Drug: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.
Trial: NCT05485584
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT05974501
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
Trial: NCT05974501
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg administered via IV once postoperatively within 24 hours for pain and swelling
Trial: NCT05040568
Drug: Expanded CB-NK cells
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05040568
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05304377
Drug: ELVN-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once or twice daily
Trial: NCT06205602
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg to be administered via IV at Step 1 (Day 1)
Trial: NCT06205602
Drug: Placebo for 3BNC117-LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
Trial: NCT06205602
Drug: Placebo for 10-1074-LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Trial: NCT06449781
Drug: Lutetium (177Lu) vipivotide tetraxetan
RxNorm normalized name: lutetium (177Lu) vipivotide tetraxetan
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
Trial: NCT05368974
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral exposure during documented pregnancy
Trial: NCT05618587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pill
Trial: NCT05256654
Drug: LY3561774
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05256654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05353179
Drug: NUCALA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUCALA® is a humanized monoclonal antibody of IgG1 injection
Trial: NCT06097169
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Trial: NCT06285214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Trial: NCT04974151
Drug: Amlodipine besylate And Folic Acid
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
Trial: NCT05000281
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg Ibuprofen 3 times a day for up to six weeks.
Trial: NCT04974151
Drug: Amlodipine folic acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
Trial: NCT06390319
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT06390319
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO.
Trial: NCT06390319
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, PO or intramuscular (IM).
Trial: NCT06452277
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral
Trial: NCT01582022
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local application for 5 minutes
Trial: NCT05072704
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
Trial: NCT05742399
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional gel having the same color, form and packaging
Trial: NCT05618119
Drug: [18F]MC225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]MC225 PET scan
Trial: NCT06308367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05772104
Drug: Shugan Jieyu Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 4 Capsules, BID
Trial: NCT05772104
Drug: Shugan Jieyu Capsules Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID
Trial: NCT05271630
Drug: Immunomodulatory Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
Trial: NCT05271630
Drug: Proteasome Inhibitor
RxNorm normalized name: Proteasome inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
Trial: NCT06239116
Drug: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
Trial: NCT06239116
Drug: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
Trial: NCT06239116
Drug: Part C: RM-718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
Trial: NCT04810819
Drug: Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
Trial: NCT04810819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00965315
Drug: Rosuvastatin,SFC fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg
Trial: NCT05679765
Drug: Greater Occipital Nerve Block with 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Trial: NCT05487404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 oral doses of placebo
Trial: NCT04685616
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT06297590
Drug: LY3954068
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IT
Trial: NCT06297590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IT
Trial: NCT06509139
Drug: Tetracycline Pill
RxNorm normalized name: tetracycline Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Trial: NCT05848258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05005793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at 0.5 mEq/kg-lean body weight/day
Trial: NCT06450262
Drug: Synjardy® 12.5mg/1000mg film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Trial: NCT05559359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given SC
Trial: NCT05559359
Drug: Topical Corticosteroid (TCS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCS administered
Trial: NCT06657768
Drug: LY4006895
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06657768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06220669
Drug: LY3541860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06220669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04535609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT05943535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered QID
Trial: NCT05679908
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will spray placebo nasal spray once into each nostril.
Trial: NCT05592275
Drug: LY3540378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05592275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06379971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Trial: NCT06379971
Drug: Choline
RxNorm normalized name: Choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Trial: NCT05713877
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
Trial: NCT04803539
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
Trial: NCT04803539
Drug: capecitabine + camrelizumab + apatinib
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Trial: NCT05713877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
Trial: NCT06205719
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2ug/kg Remifentanil